Brief: Innate Pharma Receives EMA PRIME Designation For Lacutamab In Sezary Syndrome
13/11/2020 06:02
Nov 13 (Reuters) - Innate Pharma SA IPH.PA :
* REG-INNATE PHARMA RECEIVES PRIME DESIGNATION FROM THE EUROPEAN MEDICINES AGENCY FOR
LACUTAMAB IN
SÉZARY SYNDROME
Source text for Eikon: ID:nGNE6hY9zK
Further company coverage: IPH.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Innate Pharma SA
See all newsFrance's Innate Pharma posts lower 2025 revenue as key contracts decline
Brief: Innate Pharma FY Operating Expenses EUR -63.013 Million
Brief: Innate Pharma Sa Says Sanofi to invest up to 15 million Euros In Innate Pharma
Brief: Innate Pharma Says Jonathan Dickinson To Be Appointed CEO And Board Member
French and Benelux stocks-Factors to watch